Video Library

Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.

Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.

Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.

Dr. Alice Shaw joined GRACE to discuss the changing landscape of first-line treatment of ALK-positive advanced non-small cell lung cancer.

Dr. Alice Shaw joined GRACE to discuss patterns of resistance in ALK positive non small cell lung cancer.

Dr. Karen Reckamp, MD, MS, City of Hope Comprehensive Cancer Center in Duarte, California joined GRACE to discuss the role of immunotherapy for previously treated patients with non-small cell lung cancer.

In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss PDL1 as a biomarker for second-line treatment.

In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss PDL1 as a biomarker for first-line treatment.

In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss combinations for first-line treatment - immunotherapy combined.

Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss combinations for first-line treatment - immunotherapy with chemotherapy.

Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).

Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses the role for immunotherapy in patients with a driver mutation.

Nathan Pennell, MD, PhD , Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses liquid biopsies for EGFR T790 non-small cell lung cancer (NSCLC). We would like to thank the following companies for their support of this program

Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses if immunotherapy should stop in responding patients after a fixed duration of treatment.